Electra Therapeutics (ETRA) closed at $8.64 on October 29, 2026, down 3.8% from the previous close, on volume of 159,148 shares (30-day average 633,714).
Data as of October 29, 2026.
Russell 2000 estimated to add 107 stocks in December rebalance - Stephens
Seeking Alpha News (Thu, 29-Oct 3:12 PM ET)
H.C. Wainwright Initiates a Buy Rating on Electra Therapeutics Inc. (ETRA)
TipRanks (Mon, 26-Oct 11:45 AM ET)
Business Wire (Fri, 23-Oct 7:00 AM ET)
Electra Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company's pipeline includes Ipsoprubart and ELA822.
Electra Therapeutics trades on the NASDAQ stock market under the symbol ETRA.
As of October 30, 2026, ETRA stock price declined to $8.55 with 1,018 million shares trading.
ETRA has a market cap of $536.66 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that ETRA belongs to (by Net Assets): VTI, VXF, VTWO, VTWG, VTWV.
ETRA support price is $8.15 and resistance is $9.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ETRA shares will trade within this expected range on the day.
